Table 3. Baseline characteristics according to AR expression (N=37).
| Low AR expressionN=20 (%) | High AR expressionN=17 (%) | p-value | |
|---|---|---|---|
| Age (median) | .942 | ||
| Range | |||
| <40 years old | 8 (40.0) | 7 (41.2) | |
| ≥40 years old | 12 (60.0) | 10 (58.8) | |
| Histology | .504 | ||
| Invasive ductal carcinoma | 19 (95.0) | 15 (88.2) | |
| Other | 1 (5.0) | 2 (11.8) | |
| Subtype | .001 | ||
| ER+HER2- | 4 (20.0) | 8 (47.1) | |
| ER+HER2+ | 1 (5.0) | 4 (23.5) | |
| ER-HER2- | 13 (65.0) | 0 (0.0) | |
| ER-HER2+ | 2 (10.0) | 5 (29.4) | |
| Intrinsic subtype | .001 | ||
| Luminal A | 3(15.0) | 4 (23.5) | |
| Luminal B | 0 (0.0) | 6 (35.3) | |
| Basal-like | 13 (65.0) | 1 (2.7) | |
| Normal-like | 1 (5.0) | 1 (2.7) | |
| HER2-enriched | 2 (10.0) | 6 (35.3) | |
| BRCA1/2 | .349 | ||
| Wild type | 2 (10.0) | 0 (0.0) | |
| Mutated | 2 (10.0) | 1 (5.9) | |
| Not tested | 16 (80.0) | 16 (94.1) | |
| Cancer status | .080 | ||
| Recurrent | 16 (80.0) | 9 (52.9) | |
| Initially metastatic | 4 (20.0) | 8 (47.1) | |
| Visceral metastasis | .942 | ||
| Yes | 8 (40.0) | 7 (41.2) | |
| Liver metastasis | 4 (50.0) | 4 (57.1) | |
| Brain metastasis | 4 (50.0) | 3 (42.9) | |
| No | 12 (60.0) | 10 (58.8) | |
| PIK3CA (N=34) | .013 | ||
| Mutated | 2 (11.1) | 8 (50.0) | |
| Wild type | 16 (88.9) | 8 (50.0) | |
| TP53 (N=34) | .071 | ||
| Mutated | 10 (55.6) | 4 (25.0) | |
| Wild type | 8 (44.4) | 12 (75.0) |